In a report released yesterday, Maury Raycroft from Jefferies maintained a Buy rating on Imago BioSciences (IMGO – Research Report), with a price target of $37.00. The company’s shares closed last Friday at $20.00.
According to TipRanks.com, Raycroft is a 4-star analyst with an average return of 9.3% and a 40.9% success rate. Raycroft covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Theseus Pharmaceuticals, and Ayala Pharmaceuticals.
Currently, the analyst consensus on Imago BioSciences is a Moderate Buy with an average price target of $37.00.
See the top stocks recommended by analysts >>
Imago BioSciences’ market cap is currently $670.6M and has a P/E ratio of -10.90. The company has a Price to Book ratio of 2.94.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Imago BioSciences Inc is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. It is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (ET) and myelofibrosis (MF).
Read More on IMGO: